FSTX · F-Star Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.13M | $0 | $2.55M | - | $9.20M | $543.0K | $1.35M | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.67M | $8.72M | $8.04M | - | $5.11M | $8.44M | $7.27M | - | $2.52M | $3.20M |
| SG&A | $5.16M | $7.46M | $5.70M | - | $5.24M | $6.50M | $6.43M | - | $2.83M | $2.16M |
| Total Operating Expenses | $14.83M | $16.18M | $13.74M | - | $10.35M | $14.94M | $13.70M | - | $5.35M | $5.37M |
| D&A | - | - | $122.0K | - | - | - | $144.0K | - | $96.0K | $95.0K |
| Operating Income | ($13.71M) | ($16.18M) | ($11.19M) | - | ($9.60M) | ($14.94M) | ($10.78M) | - | ($5.35M) | ($5.37M) |
| Interest Expense | $378.0K | $334.0K | $87.0K | - | - | - | - | - | - | $35.0K |
| Income Tax | $0 | $0 | - | - | $124.0K | $82.0K | $108.0K | - | - | - |
| Net Income | ($18.41M) | ($18.99M) | ($12.09M) | - | ($10.79M) | ($15.65M) | ($9.87M) | - | ($5.36M) | ($6.54M) |
| EPS - Basic | ($0.52) | ($0.88) | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.84) | ($0.88) | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $35.57M | $52.96M | $68.80M | $78.55M | $71.05M | $81.65M | $3.68M | $18.53M | $9.99M | $8.53M |
| Accounts Receivable | - | - | - | - | - | - | $0 | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.50M | $4.05M | $4.31M | $3.08M | $1.57M | $2.43M | $4.08M | $4.60M | $3.13M | $2.53M |
| Current Assets | $49.61M | $64.86M | $77.29M | $84.74M | $76.16M | $85.32M | $13.80M | $26.07M | $22.58M | $26.24M |
| Total Assets | $83.72M | $100.64M | $114.71M | $123.02M | $114.80M | $124.97M | $53.44M | $63.61M | $27.24M | $31.09M |
| Current Liabilities | $14.68M | $15.32M | $12.65M | $12.13M | $8.84M | $9.95M | $14.31M | $16.98M | $6.25M | $5.13M |
| Long-term Debt | $8.53M | $9.61M | $9.68M | $9.61M | $9.54M | $0 | - | - | - | - |
| Total Liabilities | $26.78M | $29.01M | $26.54M | $26.16M | $24.72M | $25.98M | $18.60M | $20.61M | $8.93M | $7.86M |
| Stockholders' Equity | $56.94M | $71.64M | $88.16M | $96.86M | $90.08M | $98.99M | $34.84M | $42.99M | $18.31M | $23.23M |
| Retained Earnings | ($127.94M) | ($109.53M) | ($90.54M) | ($78.45M) | ($83.19M) | ($72.69M) | ($57.04M) | ($47.17M) | ($146.25M) | ($140.89M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($11.62M) | - | - | - | ($14.38M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | ($252.0K) | - | - | - |
| Financing Cash Flow | - | - | $1.88M | - | - | - | $0 | - | - | - |
| CapEx | - | - | - | - | - | - | $267.0K | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($14.64M) | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1218.3% | - | -438.6% | - | -104.4% | -2751.0% | -795.5% | - | - | - |
| EBITDA margin | - | - | -433.8% | - | - | - | -784.9% | - | - | - |
| Net margin | -1636.2% | - | -473.8% | - | -117.4% | -2882.0% | -728.3% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | -1080.8% | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 1.48 | - | - | - |
| R&D / Revenue | 859.6% | - | 315.1% | - | 55.6% | 1553.8% | 536.3% | - | - | - |
| SG&A / Revenue | 458.8% | - | 223.5% | - | 57.0% | 1197.2% | 474.5% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -22.0% | -18.9% | -10.5% | - | -9.4% | -12.5% | -18.5% | - | -19.7% | -21.0% |
| Return on equity | -32.3% | -26.5% | -13.7% | - | -12.0% | -15.8% | -28.3% | - | -29.3% | -28.2% |
| Return on invested capital | -16.5% | -15.7% | - | - | -7.6% | -11.9% | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.38 | 4.23 | 6.11 | 6.98 | 8.62 | 8.57 | 0.96 | 1.54 | 3.62 | 5.11 |
| Quick ratio | 3.38 | 4.23 | 6.11 | 6.98 | 8.62 | 8.57 | 0.96 | 1.54 | 3.62 | 5.11 |
| Cash ratio | 2.42 | 3.46 | 5.44 | 6.47 | 8.04 | 8.20 | 0.26 | 1.09 | 1.60 | 1.66 |
| Leverage | ||||||||||
| Debt / Equity | 0.15 | 0.13 | 0.11 | 0.10 | 0.11 | 0.00 | - | - | - | - |
| Debt / Assets | 0.10 | 0.10 | 0.08 | 0.08 | 0.08 | 0.00 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -36.3x | -48.4x | -128.6x | - | - | - | - | - | - | -153.4x |
| Equity multiplier | 1.47 | 1.40 | 1.30 | 1.27 | 1.27 | 1.26 | 1.53 | 1.48 | 1.49 | 1.34 |
| Liabilities / Assets | 0.32 | 0.29 | 0.23 | 0.21 | 0.22 | 0.21 | 0.35 | 0.32 | 0.33 | 0.25 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | 0.00 | 0.02 | - | 0.08 | 0.00 | 0.03 | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | 0d | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -87.8% | -100.0% | 88.3% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -42.8% | -8.3% | -3.8% | - | -79.5% | -178.3% | -31.7% | - | 28.5% | 45.0% |
| Net income growth (YoY) | -70.6% | -21.4% | -22.5% | - | -101.4% | -139.1% | -20.7% | - | 22.5% | -43.7% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | -103.9% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -36.8% | -27.6% | 153.1% | 125.3% | 391.9% | 326.1% | 23.2% | 21.0% | -56.8% | -51.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Geographic
$18.25M totalUS$17.50M · 95.9%
SE$500.0K · 2.7%
Other$250.0K · 1.4%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing F-star Therapeutics against the 5 most active filers in the same SIC group.